CTIC [NASD]
CTI BioPharma Corp.
Index- P/E- EPS (ttm)-1.22 Insider Own0.22% Shs Outstand114.39M Perf Week-0.17%
Market Cap662.32M Forward P/E121.25 EPS next Y0.05 Insider Trans-97.35% Shs Float114.16M Perf Month-11.95%
Income-120.80M PEG- EPS next Q-0.15 Inst Own80.00% Short Float13.82% Perf Quarter0.00%
Sales14.60M P/S45.36 EPS this Y-47.40% Inst Trans46.91% Short Ratio3.39 Perf Half Y22.53%
Book/sh-0.05 P/B- EPS next Y106.20% ROA-109.90% Target Price10.74 Perf Year90.82%
Cash/sh0.84 P/C6.91 EPS next 5Y- ROE- 52W Range1.43 - 7.80 Perf YTD134.68%
Dividend- P/FCF- EPS past 5Y10.20% ROI- 52W High-26.15% Beta0.91
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin91.80% 52W Low302.80% ATR0.41
Employees121 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)45.32 Volatility6.64% 6.34%
OptionableYes Debt/Eq- EPS Q/Q2.00% Profit Margin- Rel Volume0.53 Prev Close5.82
ShortableYes LT Debt/Eq- EarningsAug 08 AMC Payout- Avg Volume4.65M Price5.76
Recom1.60 SMA20-5.81% SMA50-7.60% SMA20026.58% Volume2,172,379 Change-1.03%
Sep-01-22Initiated Jefferies Buy $13
Jul-07-22Initiated Cowen Outperform $10
Aug-09-21Initiated BTIG Research Buy $7
May-06-21Initiated Stifel Buy $5.50
Jun-24-20Resumed JMP Securities Mkt Outperform $3
Mar-05-19Initiated Lake Street Buy $4
Mar-26-18Initiated Needham Buy $10
Mar-07-18Initiated JMP Securities Mkt Outperform $8
Sep-12-17Initiated Jefferies Buy $7.50
Feb-10-16Downgrade WallachBeth Hold → Sell
Feb-10-16Downgrade Piper Jaffray Overweight → Neutral
Feb-10-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-09-15Downgrade WallachBeth Buy → Hold $4.50 → $1.60
Aug-05-14Upgrade WallachBeth Hold → Buy $4.50
Mar-19-14Initiated WallachBeth Hold $4.50
Nov-04-13Initiated HC Wainwright Buy $4
Sep-21-22 09:09PM
06:00PM
Aug-22-22 04:05PM
Aug-09-22 06:23PM
Aug-08-22 06:55PM
04:05PM
Aug-01-22 08:37AM
Jul-21-22 05:25PM
Jul-07-22 06:21PM
Jun-14-22 04:05PM
Jun-10-22 07:00AM
Jun-03-22 08:00AM
Jun-02-22 04:05PM
May-27-22 04:05PM
May-26-22 05:00PM
May-13-22 12:19PM
May-12-22 05:45PM
04:05PM
May-10-22 07:00AM
May-05-22 04:05PM
Apr-28-22 04:05PM
Apr-14-22 07:00AM
Apr-06-22 04:05PM
Mar-31-22 05:15PM
04:01PM
Mar-16-22 10:00AM
Mar-02-22 04:05PM
Feb-28-22 08:02PM
07:18PM
Feb-18-22 04:05PM
Jan-06-22 04:30PM
Dec-13-21 09:00AM
Dec-11-21 11:59AM
Dec-03-21 07:24AM
Dec-02-21 04:30PM
10:28AM
Dec-01-21 01:41PM
Nov-30-21 05:30PM
Nov-29-21 07:00AM
Nov-26-21 08:53AM
Nov-09-21 04:05PM
Nov-04-21 09:01AM
Oct-14-21 04:05PM
06:57AM
Oct-05-21 10:05AM
Oct-04-21 12:22PM
Oct-01-21 04:05PM
Sep-28-21 04:05PM
Sep-17-21 04:05PM
Sep-08-21 09:10PM
Aug-26-21 04:52PM
Aug-25-21 07:30AM
07:00AM
Aug-24-21 07:00AM
Aug-07-21 10:30PM
Aug-05-21 04:05PM
Jul-29-21 07:00AM
Jul-26-21 04:30PM
Jul-09-21 12:48AM
Jun-23-21 04:30PM
Jun-09-21 06:45PM
07:00AM
Jun-02-21 12:00AM
Jun-01-21 04:05PM
09:33AM
07:00AM
May-26-21 04:30PM
May-14-21 10:25AM
May-12-21 08:34PM
May-05-21 07:00AM
Apr-21-21 11:28PM
Apr-07-21 07:00AM
Apr-02-21 03:54PM
Mar-31-21 11:50PM
04:41PM
07:00AM
Mar-22-21 01:00PM
10:01AM
Mar-17-21 04:05PM
Mar-12-21 07:00AM
Mar-08-21 11:18PM
Feb-24-21 06:30PM
Feb-10-21 11:55PM
Jan-28-21 10:58PM
Jan-01-21 07:04AM
Dec-08-20 07:00AM
Dec-06-20 12:30PM
Dec-02-20 10:24PM
Nov-30-20 07:00AM
Nov-10-20 04:05PM
02:30PM
Nov-04-20 11:41AM
Nov-02-20 04:05PM
Oct-26-20 11:55PM
Oct-13-20 07:00AM
Oct-01-20 06:52PM
Sep-30-20 07:45AM
Sep-29-20 04:05PM
Aug-06-20 04:05PM
Jul-17-20 09:54AM
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIRSKE DAVIDEVP, Chief Financial OfficerSep 16Option Exercise0.9522,59221,43839,505Sep 20 04:59 PM
KIRSKE DAVIDEVP, Chief Financial OfficerSep 16Sale6.0222,592136,00416,913Sep 20 04:59 PM
Craig Adam RPresident and CEOSep 12Option Exercise0.84242,300203,799270,161Sep 14 04:35 PM
Craig Adam RPresident and CEOSep 12Sale6.43242,3001,557,98927,861Sep 14 04:35 PM
Craig Adam RPresident and CEOAug 16Buy5.505,00027,50027,861Aug 16 04:07 PM
BVF PARTNERS L P/ILDirectorAug 09Sale6.121,289,4347,891,3366,148Aug 11 05:52 PM
BVF PARTNERS L P/ILDirectorAug 09Sale6.127,210,56644,128,66419,839Aug 11 05:52 PM
Metzger Michael ADirectorJul 07Sale6.5120,121130,9950Jul 11 04:51 PM
Craig Adam RPresident and CEOJul 06Option Exercise0.8418,22315,32741,084Jul 06 05:19 PM
Craig Adam RPresident and CEOJul 06Sale6.1118,223111,34322,861Jul 06 05:19 PM
Craig Adam RPresident and CEOJul 05Option Exercise0.8427,00022,71049,861Jul 06 05:19 PM
Metzger Michael ADirectorJul 05Option Exercise0.8491,50076,961111,621Jul 07 05:02 PM
Metzger Michael ADirectorJul 05Sale6.0891,500556,06720,121Jul 07 05:02 PM
Craig Adam RPresident and CEOJul 05Sale6.0027,000162,00022,861Jul 06 05:19 PM
Craig Adam RPresident and CEOJul 01Option Exercise0.8427,00022,71049,861Jul 06 05:19 PM
Craig Adam RPresident and CEOJul 01Sale6.0027,000162,00022,861Jul 06 05:19 PM
KIRSKE DAVIDEVP, Chief Financial OfficerJun 17Option Exercise2.9260,000175,00057,397Jun 17 04:57 PM
KIRSKE DAVIDEVP, Chief Financial OfficerJun 17Sale6.2160,000372,5057,397Jun 17 04:57 PM
KIRSKE DAVIDEVP, Chief Financial OfficerJun 14Option Exercise0.9510,0009,48917,397Jun 16 04:19 PM
KIRSKE DAVIDEVP, Chief Financial OfficerJun 14Sale5.5010,00055,0007,397Jun 16 04:19 PM
Craig Adam RPresident and CEOJun 03Option Exercise0.8418,22315,32734,901Jun 03 06:16 PM
Craig Adam RPresident and CEOJun 03Sale6.0118,223109,52016,678Jun 03 06:16 PM
Craig Adam RPresident and CEOJun 02Option Exercise0.8427,00022,71043,678Jun 03 06:16 PM
Craig Adam RPresident and CEOJun 02Sale6.0027,000162,00016,678Jun 03 06:16 PM
Craig Adam RPresident and CEOJun 01Option Exercise0.8427,00022,71043,678Jun 03 06:16 PM
Craig Adam RPresident and CEOJun 01Sale6.0027,000162,00016,678Jun 03 06:16 PM
Craig Adam RPresident and CEODec 02Buy1.523,5005,33713,500Dec 02 05:16 PM